TransMedics Group, Inc. (TMDX)
NasdaqGM · USD · Healthcare · Medical Devices
$69.73 (-1.27%) as of
Key statistics
- Market cap
- 2.42B
- P/E (TTM)
- 18.06
- Forward P/E
- 30.93
- EPS (TTM)
- 3.86
- Dividend yield
- 0.00%
- 52-week range
- 60.10 – 156.00
- Beta
- 1.93
- Revenue (TTM)
- 668.47M
- Profit margin
- 22.69%
- Analyst target
- $98.73
- Volume
- 825.53k
About TransMedics Group, Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Andover, MA, United States
- Employees
- 898
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.